Conference Correspondent  - ESMO 2018, ESMO

Ovarian cancer treatment is associated with psychological morbidity.1 In this study, Blagden and colleagues prospectively studied the impact of a brief course of psychological support on self-reported depression, fear of progression (FoP), and quality of life (QOL) in patients following chemotherapy for primary or recurrent ovarian cancer.2

Patients were consented at their first post-chemotherapy appointment and were eligible if they scored from 5 to 19 on the PHQ9 questionnaire. They were then randomized 1:1 to the intervention or control group. Intervention was comprised of 3 standardized, 90-minute sessions of psychological support given 6 to 12 weeks after chemotherapy. Control was standard of care in which support was provided where indicated; unblinded block randomization was used for primary or recurrent ovarian cancer and 3 levels of PHQ9 as stratification factors. Patients completed PHQ9, FoP-Q-SF, EORTC QLQ C30, and OV28 questionnaires for up to 2 years, with the primary end point being change in PHQ9 score at 3 months compared with baseline.

Of the 182 patients registered, 107 were eligible and subsequently randomized: 54 to intervention and 53 to control groups. The mean age of enrolled women was 59 years. Seventy percent had primary disease and 30% had relapsed disease. Sixty-three patients completed baseline and 3-month questionnaires and were included in the analysis: 31 in the control and 32 in the intervention groups. At 3 months, there was an improvement in the PHQ9 and the Global Health Status/QOL scale for patients in both arms compared with baseline, but no significant difference was observed between the intervention and control groups. There was a significant improvement on FoP-Q-SF scores in the intervention arm; however, for patients in the control arm, FoP-Q-SF scores deteriorated at 3 months (intervention effect = –5.2; 95% confidence interval, –8.45 to 1.9; P = .003).

Overall, although symptoms of depression improved following completion of chemotherapy for patients in both arms of the study, fear of progression did not. The results presented here represent the first randomized trial of a survivorship intervention in ovarian cancer and demonstrates that fear of progression is a prominent concern for patients, which may be overcome with provision of psychological support immediately after chemotherapy.


References

  1. Gonçalves V, et al. Br J Cancer. 2008;99(11):1794-1801.
  2. Blagden S, et al. ESMO 2018. Abstract 940O.
Related Items
5-Year Follow-Up Study Confirms Safety and Efficacy of Trastuzumab Biosimilar in Patients with HER2-Positive Breast Cancer
William King
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ESMO
Bevacizumab Biosimilar Demonstrates Therapeutic Equivalence to Reference Drug in Patients with Late-Stage NSCLC
Anne Rowe
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ESMO
Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
Web Exclusives published on February 24, 2020 in ESMO
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives published on October 28, 2019 in ESMO, Breast Cancer
Adjuvant Innovative Peptide Vaccine Therapy Shows Promising Activity in Early-Stage Triple Negative Breast Cancer
Conference Correspondent  published on November 5, 2018 in ESMO 2018 Wrap Up, ESMO
Breaking News from the 2018 Meeting of the European Society for Medical Oncology (ESMO)
Conference Correspondent  published on October 22, 2018 in ESMO 2018 Wrap Up, ESMO
A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018, ESMO
A Phase 1b and Randomized Phase 2 Trial of Pazopanib with or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018, ESMO
The Efficacy of Apatinib Treatment for Advanced Ovarian Cancer After Second-Line Chemotherapy Failure
Conference Correspondent  published on October 22, 2018 in ESMO 2018, ESMO
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018, ESMO
Last modified: July 22, 2021